Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 4Cisplatin 3pembrolizumab 2fludarabine 2apatinib 2XELOX 2S 1 (combination) 2Paclitaxel 2Oxaliplatin 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Irinotecan 2Injections 2Gemcitabine 2Fulvestrant 2Epirubicin 2Drug Therapy 2Boron Neutron Capture Therapy 2titanium silicide 1tislelizumab 1surufatinib 1sintilimab 1pegfilgrastim 1nimotuzumab 1ipatasertib 1ferumoxides 1famitinib 1eribulin 1dalpiciclib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER_GOV × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Sheba Medical Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡